CytoDyn’s Chief Medical Officer Dr. Scott Kelly to Present at Triple Negative Breast Cancer Drug Development Digital Summit 2021 on April 28
27 avr. 2021 16h01 HE
|
CytoDyn Inc.
VANCOUVER, Washington, April 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140),...
CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants
22 avr. 2021 23h52 HE
|
CytoDyn Inc.
Company Achieves Total Financing in April of $57 Million VANCOUVER, Washington, April 22, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage...
CytoDyn Submits First and Most Crucial Section (CMC) of Interim Order Application to Health Canada for COVID-19 Under Rolling Review
19 avr. 2021 06h05 HE
|
CytoDyn Inc.
Clinical trial in U.S. for critically ill COVID-19 patients expected to initiate soon CytoDyn in discussions with Brazil to initiate two COVID-19 trials, one for severe and one for critically ill...
Former President of the Philippines, Joseph Estrada, Among the Many COVID-19 Patients Receiving Leronlimab Under CSP in the Philippines
19 avr. 2021 06h00 HE
|
CytoDyn Inc.
CytoDyn is following all patients treated with leronlimab under CSP and will provide additional information when available and authorized for release VANCOUVER, Washington, April 19, 2021 (GLOBE...
CytoDyn Executes Exclusive Supply and Distribution Agreement with Chiral Pharma Corporation to Provide Up to 200,000 vials of Leronlimab to Philippines
15 avr. 2021 09h26 HE
|
CytoDyn Inc.
Under Compassionate Special Permit (CSP) in Philippines, CytoDyn is well positioned to generate significant revenues VANCOUVER, Washington., April 15, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:...
CytoDyn’s COVID-19 Long-Hauler’s Trial Closed as Enrollment Exceeds Goals
08 avr. 2021 17h41 HE
|
CytoDyn Inc.
VANCOUVER, Washington, April 08, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...
CytoDyn Providing Leronlimab to a Philippine Hospital for 28 More COVID-19 Patients under Compassionate Special Permit (CSP)
07 avr. 2021 16h01 HE
|
CytoDyn Inc.
CytoDyn also negotiating the potential future delivery of 100,000 vials to the Philippines for additional CSP use VANCOUVER, Washington, April 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:...
CytoDyn Signs Exclusive Supply and Distribution Agreement with Biomm S.A. in Brazil for COVID-19 and All Other Leronlimab Indications
07 avr. 2021 06h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, April 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...
CytoDyn Reschedules Webcast from April 6 to April 7
05 avr. 2021 16h29 HE
|
CytoDyn Inc.
VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a...
CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants to Accelerate Manufacturing of Leronlimab Inventory
05 avr. 2021 06h05 HE
|
CytoDyn Inc.
VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5...